Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

SCLC, Limited Stage 1Pancreatic Neoplasms 1Neuromuscular Diseases 1Neoplasms 1Myasthenia Gravis 1Breast Neoplasms 1Autoimmune Diseases 1

Interventions

telitacicept 3rozanolixizumab 3talquetamab 1ravulizumab 1efgartigimod alfa 1blinatumomab 1Therapeutics 1Pyridostigmine Bromide 1Psychodrama 1Prednisone 1Population Groups 1Art Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Myasthenia Gravis × Population Groups × Clear all
NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡